ACTIV

ACTIV
Name	ACTIV
Formation	2020
Type	Public–private partnership
Headquarters	United States
Purpose	Coordinate COVID-19 therapeutic and vaccine trials
Region served	Global

ACTIV ACTIV was established in 2020 as a major public–private partnership to accelerate development of therapeutics, vaccines, and diagnostics for SARS-CoV-2 and COVID-19. It brought together pharmaceutical companies, research institutions, regulatory agencies, and funders to harmonize clinical trial design, prioritize candidate agents, and streamline regulatory pathways. ACTIV coordinated large-scale platform trials, adaptive designs, and data-sharing initiatives to reduce duplication and speed evidence generation.

Background

ACTIV emerged during the global COVID-19 pandemic when leaders from Operation Warp Speed, National Institutes of Health, Department of Health and Human Services, Biomedical Advanced Research and Development Authority, and major pharmaceutical companies sought to align efforts. Influenced by lessons from the Ebola virus epidemic in West Africa and the H1N1 influenza pandemic, the initiative aimed to integrate capabilities from Pfizer (company), Moderna, Inc., AstraZeneca, Johnson & Johnson, Merck & Co., Inc., and biotechnology firms. The model drew on precedents such as the Coalition for Epidemic Preparedness Innovations, Gavi, the Vaccine Alliance, and research consortia like the International Severe Acute Respiratory and Emerging Infection Consortium. Early participants included academic centers such as Johns Hopkins University, Harvard Medical School, University of Oxford, and network partners like the National Institutes of Allergy and Infectious Diseases and Fred Hutchinson Cancer Research Center.

Organization and Structure

ACTIV organized working groups and task forces linking industry R&D teams from GlaxoSmithKline and Regeneron Pharmaceuticals with regulatory staff from the Food and Drug Administration and scientific leadership at the National Institutes of Health. Governance structures incorporated input from funders including the Bill & Melinda Gates Foundation, the Wellcome Trust, and the European Commission, while operations interfaced with trial networks such as the National Clinical Trials Network and the Vaccine Safety Datalink. The initiative used adaptive platform trial methods inspired by designs applied in the RECOVERY Trial and the SOLIDARITY Trial, aligning clinical endpoints with standards from agencies like the European Medicines Agency and the World Health Organization. Operational arms included protocol harmonization, master protocol drafting, and centralized data-sharing overseen by data stewards from institutions including Broad Institute and Scripps Research.

ACTIV Clinical Trial Programs

ACTIV supported multiple trial programs that ran parallel or integrated studies of antivirals, monoclonal antibodies, immune modulators, and vaccine strategies. Programs tested candidates from companies such as Eli Lilly and Company and Bristol Myers Squibb alongside investigational agents developed at universities like Massachusetts Institute of Technology and Stanford University. Trials incorporated adaptive randomization and interim analyses comparable to those used in the RECOVERY Trial and employed master protocols to evaluate agents from consortia including COVID-19 Therapeutics Accelerator. ACTIV-backed studies assessed therapeutics such as remdesivir-style antivirals, monoclonal antibodies similar to those from Regeneron Pharmaceuticals, and immunomodulators used in trials coordinated with Cleveland Clinic and Mayo Clinic. Vaccine-related activities aligned with developers like Moderna, Inc. and AstraZeneca while coordinating post-authorization effectiveness studies with public health agencies including Centers for Disease Control and Prevention.

Key Partnerships and Collaborations

ACTIV convened partnerships across sectors: pharmaceutical corporations (for example Pfizer (company), Merck & Co., Inc.), academic research centers (University of California, San Francisco, Columbia University), international organizations (World Health Organization, Gavi, the Vaccine Alliance), and philanthropic funders (Bill & Melinda Gates Foundation, Wellcome Trust). It leveraged clinical trial networks such as INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) and worked with regulatory agencies like the European Medicines Agency and Food and Drug Administration to streamline pathways. Collaborations included data-sharing platforms with partners like Amazon Web Services for secure analytics and infrastructure cooperation with National Institutes of Health networks including the National Institute of Allergy and Infectious Diseases clinical trial enterprise.

Governance and Funding

Governance combined representatives from federal agencies such as the Department of Health and Human Services and National Institutes of Health with industry executives from companies including Johnson & Johnson and AstraZeneca. Advisory input came from scientific bodies like the National Academy of Medicine and institutional review from ethical committees at participating centers such as Yale School of Medicine and University of Pennsylvania. Funding streams pooled public appropriations from congressional emergency packages with private contributions from corporations and foundations including the Bill & Melinda Gates Foundation and corporate philanthropy from entities like Pfizer (company). Financial oversight and prioritization were informed by cost-effectiveness considerations aligned with health technology assessment bodies similar to National Institute for Health and Care Excellence.

Impact and Outcomes

ACTIV accelerated initiation and coordination of large platform trials, reducing redundant small studies and producing comparative data on therapeutics and vaccines that informed regulatory decisions at the Food and Drug Administration and policy guidance from the World Health Organization. Outcomes included faster enrollment for studies modeled on the RECOVERY Trial and generation of datasets that supported emergency use authorizations and full approvals involving partners such as Moderna, Inc. and Pfizer (company). The program influenced subsequent public–private partnerships during health emergencies, shaping frameworks used by organizations like the Coalition for Epidemic Preparedness Innovations and national research infrastructures at institutions such as National Institutes of Health.

Category:Public–private partnerships